euro adhoc: Intercell AG / quarterly or semiannual financial statement / Intercell AG announces Q1 results and update on development programs: Adjuvant IC31TM opens attractive new market opportunity i

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

quaterly report

14.05.2007

IC31TM - Clinical results emphasize broad and commercial use in
vaccine development

» Protective profile for IC31TM in Phase I Tuberculosis vaccine trial
- strong T-cell immune responses in humans confirming broad
pre-clinical data base » Promising pre-clinical data for the use of
IC31TM in next generation Flu vaccines - first clinical trials
planned for 2007 » Next Milestones - start of a Phase I
"proof-of-concept" clinical trial for an IC31TM adjuvanted Flu
vaccine and strong focus on a commercial use of IC31TM and further
strategic partnerships

All development projects on track and within expected timelines

» Japanese Encephalitis vaccine - all preparations for expected
market launch in the US early 2008 and late 2008 in Europe are on
track Regulatory clearance to start a pediatric Phase II clinical
trial in India obtained - start of Phase II trial within the next
few weeks » Hepatitis C vaccine - Phase II "proof-of-concept" study
fully recruited - first data expected by mid 2007 - forward
strategies comprise options for mono- and/or combination therapies
» Pneumococcus vaccine - preparations for start of Phase I clinical
trial on track

Nosocomial (hospital-acquired) infections - Building the leading
vaccine franchise

» Staphylococcus aureus vaccine partnered with Merck & Co. - safe and
immunogenic in Phase I clinical trials - Phase II expected to start
in 2007 » Pseudomonas vaccine - preparations for start of clinical
Phase II/III trials on track » Enterococcus/Klebsiella vaccines -
AIP® accelerated to progress into clinical development

Strong financial position - Net loss further reduced

» EUR 7.1 million net loss for Q1 2007 - down 19.3 percent as
compared to Q1 2006 » Increase of aggregate revenues - EUR 1.5
million in Q1 2007 compared to EUR 0.3 million in Q1 2006 » EUR 7.4
million R&D expenses in Q1 2007 - up 8.8 percent as compared to Q1
2006 » Strong cash position with EUR 86.3 million in liquid funds at
March 31, 2007

end of announcement euro adhoc 14.05.2007 06:57:42
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market